Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 20, 2025 08:30 ET | Source: Clene Inc.

Clene to Present at the Emerging Growth Conference

SALT LAKE CITY, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage...
October 15, 2025 08:30 ET | Source: Clene Inc.

Clene to Participate in a Panel Discussion at the Maxim Growth Summit

SALT LAKE CITY, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage...
September 25, 2025 08:00 ET | Source: Clene Inc.

Clene Presents New Clinical Data at ECTRIMS 2025 Meeting Demonstrating CNM-Au8® Improves Brain Energy Metabolism in Multiple Sclerosis Patients

Late-breaking clinical data presented at the 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis Across non-active progressive MS (primary progressive and...
September 04, 2025 08:30 ET | Source: Clene Inc.

Clene Presents Preclinical Data Supporting CNM-Au8® for the Treatment of Parkinson’s Disease

Novel human preclinical neuronal model for Parkinson’s disease demonstrated CNM-Au8’s ability to improve mitochondrial health, restore cellular metabolism, reduce inflammation, and normalize...
September 02, 2025 08:00 ET | Source: Clene Inc.

Clene to Present at the H.C. Wainwright 27th Annual Global Investment Conference

SALT LAKE CITY, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage...
August 14, 2025 08:38 ET | Source: Clene Inc.

Clene Reports Second Quarter 2025 Financial Results and Recent Operating Highlights

Following constructive FDA feedback on its proposed statistical analysis plan, Clene plans to analyze the neurofilament light data from its large NIH-sponsored Early Access Protocol early in the...
August 13, 2025 08:00 ET | Source: Clene Inc.

Clene to Present at the Emerging Growth Conference

SALT LAKE CITY, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage...
August 05, 2025 08:30 ET | Source: Clene Inc.

Clene to Present at the Canaccord 45th Annual Growth Conference

SALT LAKE CITY, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage...
June 30, 2025 08:00 ET | Source: Clene Inc.

Clene Provides Regulatory Update Following Constructive FDA Type-C Meeting on Neurofilament Biomarker Analysis Plan and Confirms Two Additional FDA Meetings

FDA provides supportive feedback on proposed statistical analysis plan for neurofilament biomarker analysis of Clene’s NIH-sponsored Expanded Access ProgramNfL EAP biomarker analyses to be conducted...
May 07, 2025 08:00 ET | Source: Clene Inc.

Clene Reports First Quarter 2025 Financial Results and Recent Operating Highlights

Clene preparing for upcoming meeting in the second quarter with the U.S. Food and Drug Administration (FDA) to reach agreement on its statistical analysis plan (SAP) regarding analysis of...